Vertex Pharmaceuticals’ Journavx Wins Award at 2025 AAHKS Annual Meeting

In this episode of AAHKS Amplified, host Cory L. Calendine, MD had the pleasure of sitting with Jenna Harrington of Vertex Pharmaceuticals to discuss JOURNAVX® (suzetrigine). Vertex won the 2025 AAHKS Industry Innovation Award. An award presented each year at the AAHKS Annual Meeting to companies with cutting-edge innovations in the field of orthopaedic hip and knee arthroplasty by exhibitors. 

Journavx is an oral, non-opioid, highly selective pain signal inhibitor that is selective for NaV1.8 relative to other NaV channels. Because JOURNAVX blocks pain signals only found in the periphery, not in the brain, JOURNAVX provides effective relief of pain without the limitations of currently available therapies, including the addictive potential of opioids.

For more information on Journavx and how they are transforming the landscape of pain management, tune in for the full recording. Don’t forget to subscribe and thanks for listening to AAHKS Amplified!

In This Episode:
Cory L. Calendine, MD 
Jenna Harrington